A 23-Year-Old in Louisiana Was Functionally Cured of Sickle Cell Disease
Sickle cell disease blocked Daniel Cressy's path to becoming a commercial pilot. After Casgevy gene therapy, the 23-year-old is working toward that future again.
Topics
- Published
- Jun 24, 2026, 9:14 AM EDT
- Updated
- Jul 28, 2026, 12:00 PM EDT
- Reviewed
- Jul 28, 2026
- Status
- Confirmed
- Original source
- Manning Family Children's
- VV source card
- Source graph record
- Verification
- Corroborated reporting
- Confidence
- very high
- Urgency
- very high
Rapid orientation
The 5-second read
- What happened
- Manning Family Children's says Cressy received Casgevy, an FDA-approved CRISPR/Cas9 gene-editing therapy for eligible sickle cell patients. His treatment required stem-cell collection, lab modification in Scotland, chemotherapy, reinfusion, inpatient recovery, and follow-up.
- Why it matters
- This affects how patients, clinicians, regulators, or families may talk about Gene Therapy right now.
- Status
- Confirmed
- Overclaim risk
- Medium
- Primary source
- Manning Family Children's (Official)
- Next thing to watch
- Longer follow-up, progress toward Cressy's FAA medical clearance, and whether specialist-center access expands.
Signal context
Known so far
- Patient
- Daniel Cressy, 23
- Location
- Metairie / New Orleans, Louisiana
- Treatment site
- Manning Family Children's Hospital
- Reported outcome
- First patient in Louisiana and the Gulf South reported functionally cured
- Treatment
- Casgevy CRISPR/Cas9 gene-editing therapy
- Timeline
- Three-day stem-cell collection began July 30, 2025; edited cells returned March 2026; reinfused March 18; discharged mid-April
- Timeline source note
- Contemporaneous July 2025 reporting is used for the exact collection date; the hospital's June 2026 retrospective described it more broadly as late 2025
- Three-month update
- Hospital reported his hemoglobin was the highest it had ever been
- Source framing
- Life 2 and restoring his dream of becoming a pilot
- Local burden
- Louisiana has more sickle cell disease cases per capita than any other U.S. state, per the hospital source
VV Brief Matrix v1.0
VV Brief Signal Score
A derived editorial signal score for how timely, source-backed, important, and bounded this brief is. It helps explain why we covered the story now. It is not a medical evidence score or treatment recommendation.
85/100
Breakout Brief
- Source proximity
- 92/100, weight 18%
- Verification strength
- 82/100, weight 20%
- News cycle urgency
- 96/100, weight 14%
- Human/share signal
- 95/100, weight 12%
- Clinical/scientific importance
- 90/100, weight 16%
- Follow-up value
- 88/100, weight 12%
- Confidence
- 94/100, weight 8%
This brief scores high because news cycle urgency, human/share signal, confidence, but an overclaim penalty of 5 keeps the framing bounded.
Claim Check
ConfirmedDaniel Cressy became the first patient in Louisiana and the Gulf South reported functionally cured of sickle cell disease after Casgevy CRISPR/Cas9 gene-editing therapy.
Safe framing
Manning Family Children's says Cressy received Casgevy, an FDA-approved CRISPR/Cas9 gene-editing therapy for eligible sickle cell patients. His treatment required stem-cell collection, lab modification in Scotland, chemotherapy, reinfusion, inpatient recovery, and follow-up.
What happened
Manning Family Children's says Daniel Cressy, 23, became the first patient in Louisiana and the Gulf South to receive Casgevy CRISPR/Cas9 gene-editing therapy for sickle cell disease.
The pilot angle is the emotional center. Sickle cell disease had blocked his FAA medical path toward becoming a commercial pilot. After more than two years of treatment steps, he is working toward that future again.
Contemporaneous reporting documented his three-day stem-cell collection beginning July 30, 2025. Manning Family Children's later summarized the collection as occurring in late 2025. The edited cells returned from Scotland in March 2026 and were reinfused on March 18 after chemotherapy conditioning.
Functional cure is careful language. It does not mean every sickle cell patient is eligible, that treatment is easy, or that permanent lifetime cure has been proven.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No selling your information. Unsubscribe anytime.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
Why it matters
- This affects how patients, clinicians, regulators, or families may talk about Gene Therapy right now.
- Canonical source pages make the evidence path easier to inspect before readers open original URLs.
- The brief is useful only when the reported outcome stays separate from broad proof, access, or standard-care claims.
What not to overclaim
- Do not treat this as proof beyond the named source, population, product, institution, and follow-up window.
- Do not imply broad access, routine use, or superiority without comparative evidence.
- Do not turn patient, company, regulatory, or institutional reporting into a universal outcome claim.
Signal context
Context
- Primary topic
- Gene Therapy
- Source date
- Jun 22, 2026
- Source stack
- 5 sources
- Current status
- Confirmed
VV caution: Correction recorded July 28, 2026: the exact collection timeline now uses contemporaneous reporting from the three-day collection beginning July 30, 2025. Manning Family Children's later retrospective wording ('late 2025') remains disclosed rather than erased. Casgevy is transplant-style care, not a quick outpatient cure.
Evidence trail
Source stack
- PrimaryOfficialJun 22, 2026Manning Family Children's: Daniel Cressy receives Casgevy and makes Louisiana history
- Additional contextTrade newsAug 3, 2025News From The States / Verite: Daniel Cressy begins Casgevy stem-cell collection
- IndependentTrade newsJun 23, 2026Fox 8 / WVUE: New Orleans man becomes first in Louisiana functionally cured of sickle cell disease
- IndependentTrade newsJun 24, 2026The Guardian: Louisiana man functionally cured of sickle cell disease
- RegulatoryOfficialDec 8, 2023FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease
Research map
View associated studies
Research records connected to this brief through canonical sources, topic tags, or timeline events.
No directly linked studies are available for this page yet. Topic-only matches are not shown as evidence.
Related briefs
More brief coverage
Human Breakthrough Desk
Help us find and amplify more stories like this.
Some health stories should not vanish after one news cycle. Support the independent desk finding patient wins, medical breakthroughs, and human stories worth moving.
Support the Human Breakthrough Desk